Parecoxib perishes?
Executive Summary
FDA finds the injectable COX-2 inhibitor parecoxib "not approvable," Pfizer says Sept. 20. The company plans to meet with FDA "as soon as possible" to discuss the future of the application and says it "disagrees with the conclusions" made by FDA in the letter. FDA previously found parecoxib not approvable in 2001; that review raised questions about the product's efficacy and safety (1"The Pink Sheet" Feb. 14, 2005, p. 11)...
You may also be interested in...
FDA Discloses Safety Reviews Of COX-2s Arcoxia, Prexige and Parecoxib
Merck's Arcoxia is linked to an increase in cardiovascular adverse events across multiple analyses, FDA reviewers state in briefing documents for the upcoming COX-2 inhibitor safety review
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.